BLA 761328 · Astrazeneca Ab
Beyfortus
Nirsevimab-Alip · Injection · Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody
NovelCDER novel approval, Jul 17, 2023: To prevent respiratory syncytial virus (RSV) lower respiratory tract disease
Last checked: Nov 20, 2026Latest source record: Apr 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Jul 17, 2023
Approved uses
3
Original approval plus efficacy supplements
Registered trials
14
5 Phase 3, 8 recruiting
FAERS reports
1,793
1,142 serious, 41 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 13, 2026.
BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. BEYFORTUS is a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor indicated for the prevention of RSV lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season. ( 1 ) Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. ( 1 )
Mechanism: BEYFORTUS is a monoclonal antibody with anti-RSV activity [see Microbiology (12.4) ] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 20, 2025 Supplement 12 · Efficacy LabelLetter
- Aug 22, 2024 Supplement 5 · Efficacy LetterLabel
- Jul 17, 2023 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
2 products under this application
- BEYFORTUS · NIRSEVIMAB-ALIP 50MG · INJECTABLE, INJECTION · Prescription
- BEYFORTUS · NIRSEVIMAB-ALIP 100MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nirsevimab" as an intervention, any sponsor and status, largest first.
- Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of LifePivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT05437510 · 8,057 participants · Start Aug 8, 2022 · Primary completion Mar 27, 2024
Drug: Nirsevimab · For: RSV Immunization; Healthy Volunteer
Sites: Aix-en-Provence, France; Amiens, France; Bordeaux, France · 240 sites in all
PENTA FoundationResearch network
NCT07041190 · 1,500 participants (planned) · Start Sep 2025 · Primary completion Nov 2028
Drug: Abrysvo; Nirsevimab · For: RSV Immunization
- THRIVE - Trial of Passive Humoral RSV Immunity for Value and EffectivenessPivotal-lookingRecruiting
Menzies School of Health ResearchAcademic, hospital or other
NCT07578298 · 1,000 participants (planned) · Start Jun 17, 2026 · Primary completion Jul 31, 2030
Drug: Nirsevimab (RSV-specific monoclonal antibody) · For: Respiratory Syncytial Virus (RSV); Respiratory Infection Virus
Sites: Darwin, Australia
- Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV VaccinationPivotal-lookingRecruiting
Centre Hospitalier Annecy GenevoisAcademic, hospital or other
NCT07232706 · 1,000 participants (planned) · Start May 6, 2026 · Primary completion May 5, 2029
Drug: Nirsevimab; Abrysvo · For: RSV Immunization
Sites: La Roche-sur-Yon, France
- Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in ChinaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05110261 · 800 participants · Start Nov 24, 2021 · Primary completion Nov 24, 2025
Drug: Nirsevimab; Placebo · For: Lower Respiratory Tract Infection
Sites: Beijing, China; Changde, China; Changsha, China · 30 sites in all
- Safety of RSV Preventive Monoclonal AntibodyPivotal-lookingRecruiting
Duke UniversityAcademic, hospital or other
NCT07158814 · 524 participants (planned) · Start Oct 2, 2025 · Primary completion Feb 2027
Drug: Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody · For: Fever; Adverse Event Following Immunisation
Sites: Oakland, California; Atlanta, Georgia; New York, New York · 6 sites in all
- A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 MonthsPivotal-lookingActive, not recruiting
ModernaTX, Inc.Moderna (MRNA)
NCT05743881 · 186 participants · Start Feb 15, 2023 · Primary completion Aug 31, 2029
Drug: mRNA-1345; mRNA-1365 and 2 more · For: Respiratory Syncytial Virus; Human Metapneumovirus
Sites: Los Angeles, California; Washington D.C., District of Columbia; Melrose Park, Illinois · 17 sites in all
- The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both ProductsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT06551506 · 181 participants · Start Sep 19, 2024 · Primary completion May 5, 2026
Drug: Abrysvo; Beyfortus · For: Respiratory Syncytial Virus Infection
Sites: Atlanta, Georgia; Baltimore, Maryland; New York, New York · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective324
- respiratory syncytial virus bronchiolitis302
- respiratory syncytial virus infection251
- incorrect dose administered234
- bronchiolitis157
- pyrexia114
- cough112
- extra dose administered84
- expired product administered50
- respiratory syncytial virus test positive50
- dyspnoea46
- wheezing44
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 143 |
| 2024 | 450 |
| 2025 | 772 |
| 2026 | 428 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis.
Sumsuzzman DM, Wang Z, Langley JM, et al. · Lancet Child Adolesc Health 2025 · Systematic Review, Meta-Analysis
- Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
Hammitt LL, Dagan R, Yuan Y, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Multicenter Study
- Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.
Drysdale SB, Cathie K, Flamein F, et al. · N Engl J Med 2023 · Multicenter Study, Pragmatic Clinical Trial
- Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
Griffin MP, Yuan Y, Takas T, et al. · N Engl J Med 2020 · Multicenter Study, Randomized Controlled Trial
- Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026.
Scott J, Abers MS, Marwah HK, et al. · N Engl J Med 2025 · Systematic Review
- RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing.
Wilkins D, Wählby Hamrén U, Chang Y, et al. · Pediatrics 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.